Compare STRA & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRA | NUVB |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | 291 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 1996 | N/A |
| Metric | STRA | NUVB |
|---|---|---|
| Price | $80.68 | $4.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $92.67 | $11.38 |
| AVG Volume (30 Days) | 253.1K | ★ 3.2M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.91% | N/A |
| EPS Growth | ★ 15.85 | N/A |
| EPS | ★ 5.41 | N/A |
| Revenue | ★ $997,137,000.00 | N/A |
| Revenue This Year | $3.93 | $205.55 |
| Revenue Next Year | $4.93 | $58.57 |
| P/E Ratio | $15.25 | ★ N/A |
| Revenue Growth | ★ 57.23 | N/A |
| 52 Week Low | $72.17 | $1.57 |
| 52 Week High | $92.98 | $9.75 |
| Indicator | STRA | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 45.06 | 46.60 |
| Support Level | $78.87 | $4.06 |
| Resistance Level | $81.59 | $5.55 |
| Average True Range (ATR) | 2.37 | 0.24 |
| MACD | -0.16 | 0.08 |
| Stochastic Oscillator | 23.00 | 59.35 |
Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.